X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WOCKHARDT - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WOCKHARDT GLENMARK PHARMA/
WOCKHARDT
 
P/E (TTM) x 13.3 -21.1 - View Chart
P/BV x 2.4 1.5 161.8% View Chart
Dividend Yield % 0.4 0.0 16,833.3%  

Financials

 GLENMARK PHARMA   WOCKHARDT
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
WOCKHARDT
Mar-18
GLENMARK PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs9301,012 91.9%   
Low Rs517532 97.3%   
Sales per share (Unadj.) Rs322.6355.9 90.7%  
Earnings per share (Unadj.) Rs28.5-60.3 -47.3%  
Cash flow per share (Unadj.) Rs39.2-46.8 -83.8%  
Dividends per share (Unadj.) Rs2.000.01 20,000.0%  
Dividend yield (eoy) %0.30 21,327.9%  
Book value per share (Unadj.) Rs183.0257.8 71.0%  
Shares outstanding (eoy) m282.17110.63 255.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.2 103.4%   
Avg P/E ratio x25.4-12.8 -198.4%  
P/CF ratio (eoy) x18.5-16.5 -111.9%  
Price / Book Value ratio x4.03.0 132.1%  
Dividend payout %7.00 -42,316.6%   
Avg Mkt Cap Rs m204,20685,379 239.2%   
No. of employees `00013.76.3 219.3%   
Total wages/salary Rs m18,7189,371 199.8%   
Avg. sales/employee Rs Th6,636.86,295.0 105.4%   
Avg. wages/employee Rs Th1,364.71,498.3 91.1%   
Avg. net profit/employee Rs Th586.1-1,066.3 -55.0%   
INCOME DATA
Net Sales Rs m91,03139,369 231.2%  
Other income Rs m9141,202 76.0%   
Total revenues Rs m91,94540,571 226.6%   
Gross profit Rs m16,15418 88,272.1%  
Depreciation Rs m3,0191,495 201.9%   
Interest Rs m2,8562,555 111.8%   
Profit before tax Rs m11,193-2,830 -395.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m3,155257 1,227.5%   
Profit after tax Rs m8,039-6,669 -120.5%  
Gross profit margin %17.70 38,176.0%  
Effective tax rate %28.2-9.1 -310.3%   
Net profit margin %8.8-16.9 -52.1%  
BALANCE SHEET DATA
Current assets Rs m69,88733,796 206.8%   
Current liabilities Rs m32,87926,917 122.1%   
Net working cap to sales %40.717.5 232.7%  
Current ratio x2.11.3 169.3%  
Inventory Days Days8179 102.6%  
Debtors Days Days9389 104.8%  
Net fixed assets Rs m28,89239,664 72.8%   
Share capital Rs m282553 51.0%   
"Free" reserves Rs m51,35327,968 183.6%   
Net worth Rs m51,63528,522 181.0%   
Long term debt Rs m41,41821,731 190.6%   
Total assets Rs m125,95481,620 154.3%  
Interest coverage x4.9-0.1 -4,575.6%   
Debt to equity ratio x0.80.8 105.3%  
Sales to assets ratio x0.70.5 149.8%   
Return on assets %8.6-5.0 -171.6%  
Return on equity %15.6-23.4 -66.6%  
Return on capital %15.1-7.7 -196.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,3179,807 370.3%   
Fx outflow Rs m9,7201,789 543.4%   
Net fx Rs m26,5988,019 331.7%   
CASH FLOW
From Operations Rs m16,481684 2,408.0%  
From Investments Rs m-10,1336,302 -160.8%  
From Financial Activity Rs m-4,685-7,695 60.9%  
Net Cashflow Rs m1,770-664 -266.6%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.3 300.0%  
FIIs % 34.4 7.7 446.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   56,727 67,757 83.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Power and Energy Stocks Witness Buying(12:30 pm)

Share markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the power sector.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 25, 2019 03:37 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS